Is Advanced Accelerator Applications (NASDAQ:AAAP) a Buy or a Sell? What Does JMP Securities Think?

Share

Why Has JMP Securities Given Advanced Accelerator Applications (NASDAQ:AAAP) a $44 Price Target

JMP Securities disclosed in an analyst report that it began coverage on Advanced Accelerator Applications (NASDAQ:AAAP) stock, with Mkt Outperform rating and a $44 TP.

Approximately 3,262 shares of stock traded hands. Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) has risen 6.00% since November 7, 2015 and is uptrending. It has outperformed by 7.08% the S&P500.

Is Advanced Accelerator Applications (NASDAQ:AAAP) a Buy or a Sell? What Does JMP Securities Think?

Advanced Accelerator Applications SA is a radiopharmaceutical firm that develops, produces and sells molecular nuclear medicine , diagnostic and therapeutic products. The company has a market cap of $1.02 billion. The Company’s lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs). It currently has negative earnings. The Firm has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products.

According to Zacks Investment Research, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France.” Get a free copy of the Zacks research report on Advanced Accelerator Application SA(ADR) (AAAP).

COMMENTS: